258
Views
4
CrossRef citations to date
0
Altmetric
Treatment

Airway hyperresponsiveness to mannitol improves in both type 2 high and type 2 low asthma after specialist management

, MD, , MD, PhD, , DMSC & , PhD
Pages 1221-1228 | Received 25 Feb 2020, Accepted 03 Jun 2020, Published online: 24 Jun 2020
 

Abstract

Objectives

Type 2 low (T2-low) asthma is reported to respond less to anti-inflammatory treatment compared with Type 2 high (T2-high) asthma. Airway hyperresponsiveness (AHR) to mannitol, a marker of airway mast cell activation, may be indicative of response to treatment in patients with T2-low disease. We investigated whether AHR to mannitol improves in patients with T2-low asthma after specialist management.

Methods

Patients with asthma or suspected asthma, referred to our specialist outpatient clinic, were enrolled consecutively and assessed with FeNO, asthma control, blood eosinophils, mannitol and methacholine tests and induced sputum. T2-low asthma was defined in patients with FeNO < 25ppb and sputum eosinophils < 3% and blood eosinophils < 300µl−1 at inclusion. Patients with asthma and AHR to mannitol (PD15 ≤ 635 mg) were followed and reassessed after 12 months of specialist management.

Results

Thirty-two patients (Females: 56%, age: 22 years (15–59)) were followed. Fourteen (44%) with T2-high and 18 (56%) with T2-low asthma. Baseline AHR to mannitol was comparable: Gmean PD15: 150 mg (95% CI 61–368) and 214 mg (95% CI 106–432) for T2-high and T2-low asthma respectively (P = 0.51). Both groups improved equally: Gmean PD15: 488 mg (95% CI 311–767) and 507 mg (95% CI 345–746); corresponding to a doubling-dose of: 3.00 (95% CI 1.58–5.74, P = 0.003) and 2.28 (95% CI 1.47–3.53, P = 0.001) respectively. There were no concomitant improvements in AHR to methacholine.

Conclusion

Patients with asthma and AHR to mannitol improve similarly in responsiveness to mannitol after 12 months of specialist management regardless of Type 2 inflammatory biomarker levels. Mechanisms driving AHR in T2-low asthma need to be further elucidated.

Disclosure statement

No conflicts exist for Morten Hvidtfeldt, Asger Sverrild, Vibeke Backer or Celeste Porsbjerg.

Additional information

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,078.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.